EUVIMEDEUVIMED entdecken
Open Access

The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia

Karen Sauve, Aubrey Watson, Jun T Oh, Steven Swift, Xavier Vila-Farres, Wessam Abdelhady, Yan Q Xiong, Dario LeHoux, Gary Woodnutt, Arnold S Bayer, Raymond Schuch iD

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Karen Sauve und 10 weiteren Autor:innen. Beteiligte Einrichtung: ContraFect Corporation, Yonkers, New York. Hauptthemen laut MEDLINE: Meropenem, Anti-Bacterial Agents, Pseudomonas aeruginosa, Microbial Sensitivity Tests. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, ContraFect Corporation, Lundquist Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lysins (cell wall hydrolases) targeting gram-negative organisms require engineering to permeabilize the outer membrane and access subjacent peptidoglycan to facilitate killing. In the current study, the potential clinical utility for the engineered lysin CF-370 was examined in vitro and in vivo against gram-negative pathogens important in human infections.

Methods

Minimum inhibitory concentration (MICs) and bactericidal activity were determined using standard methods. An in vivo proof-of-concept efficacy study was conducted using a rabbit acute pneumonia model caused by Pseudomonas aeruginosa.

Results

CF-370 exhibited potent antimicrobial activity, with MIC50/90 values (in µg/mL) for: P aeruginosa, 1/2; Acinetobacter baumannii, 1/1; Escherichia coli, 0.25/1; Klebsiella pneumoniae, 2/4; Enterobacter cloacae 1/4; and Stenotrophomonas maltophilia 2/8. CF-370 furthermore demonstrated bactericidal activity, activity in serum, a low propensity for resistance, anti-biofilm activity, and synergy with antibiotics. In the pneumonia model, CF-370 alone decreased bacterial densities in lungs, kidneys, and spleen versus vehicle control, and demonstrated significantly increased efficacy when combined with meropenem (vs either agent alone).

Conclusions

CF-370 is the first engineered lysin described with potent broad-spectrum in vitro activity against multiple clinically relevant gram-negative pathogens, as well as potent in vivo efficacy in an animal model of severe invasive multisystem infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemAnti-Bacterial AgentsPseudomonas aeruginosaMicrobial Sensitivity TestsPseudomonas InfectionsPneumonia, BacterialDrug SynergismAnimalsRabbitsDisease Models, AnimalGram-Negative BacteriaBiofilms

Stichwörter der Autor:innen

Pseudomonas aeruginosaESKAPE pathogenslysinmultidrug resistancesynergy

Substanzen

MeropenemAnti-Bacterial Agents

Autor:innen und Institutionen

  • ContraFect Corporation, Yonkers, New York.
  • The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, California.
  • Geffen School of Medicine, University of California, Los Angeles.

ORCID-Profile: Raymond Schuch

Förderung

  • Wellcome Trust
  • ContraFect Corporation
  • Lundquist Institute

Zitieren

APA

Sauve, K., Watson, A., Oh, J. T., Swift, S., Vila-Farres, X., Abdelhady, W., Xiong, Y. Q., LeHoux, D., Woodnutt, G., Bayer, A. S., & Schuch, R. (2024). The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae027

Vancouver

Sauve K, Watson A, Oh JT, Swift S, Vila-Farres X, Abdelhady W, et al. The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae027

BibTeX
@article{Sauve2024,
  author = {Sauve, Karen and Watson, Aubrey and Oh, Jun T and Swift, Steven and Vila-Farres, Xavier and Abdelhady, Wessam and Xiong, Yan Q and LeHoux, Dario and Woodnutt, Gary and Bayer, Arnold S and Schuch, Raymond},
  title = {The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae027}
}
Kostenlos starten →